# MEDICIS Internal Notes

2018-09-24
18:32
 Theranostic radiolabeled nanoparticles for ovarian cancer by folate receptor targeting Patients with epithelial ovarian cancer (EOC) are frequently diagnosed at stage III/IV with widespread peritoneal carcinomatosis, and have a poor overall survival [1]. Because of current screening techniques do not provide early diagnoses of small volume disease, new methods that enhance the detection and treatment of EOC are needed to improve the prognosis of this type of patients. [...] MED-016.- Geneva : CERN, 2018 - 3. Fulltext: PDF;

2018-09-24
18:24
 44Sc production with 18 MeV cyclotron and study of scandium-labeled peptide based ligands for clinical use 44Sc and 47Sc radionuclides are promising for positron emission tomography (PET/CT) with 44Sc and 47Sc as therapeutic counterpart. It is attractive for theranostic application with 47Sc, 177Lu or 90Y as therapeutic counterparts [1]. [...] MED-015.- Geneva : CERN, 2018 - 3. Fulltext: PDF;

2018-09-24
18:15
 Labeling of heat-sensitive biomolecules with terbium radionuclides for imaging and treatment of (micro)metastatic CEA-positive colorectal cancer: selecting the optimal match between chelator and radiometal Colorectal cancer is one of the most frequently diagnosed cancers in the western world and third most common cause of cancer deaths. The use of non-invasive molecular imaging offers the advantage that the entire tumor lesion, as well as possible metastatic lesions can be detected with a single scanning procedure, providing a valuable tool for cancer staging.1 Physiological uptake of [18F]FDG, the most used PET-tracer in oncology, is frequently observed in the gastrointestinal tract, and may complicate the detection of colorectal cancer, in particular peritoneal metastases [...] MED-014.- Geneva : CERN, 2018 - 4. Fulltext: DOC;

2018-07-23
00:11
 Towards simultaneous MRI-SPECT (gamma-MRI) using highly-polarized gamma-emitting nuclei / Kowalska, Magdalena (CERN) PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), and MRI (Magnetic Resonance Imaging) are indispensable diagnostic approaches in medicine, which exhibit very complementary features. The first two techniques profit from high sensitivity of detecting particles or gamma rays but with lower spatial resolution. [...] MED-013.- Geneva : CERN, 2018 Fulltext: DOC;

2018-07-23
00:05
 Large production of Scandium and Terbium at very high specific activity for theranostics applications: combining cyclotron production with off-line mass separation / Formento Cavaier, Roberto (Centre National de la Recherche Scientifique (FR)) The new facility CERN-MEDICIS will produce isotopes using the CERN proton beam at 1.4 GeV coming from the CERN Proton Booster. However, during short and long shutdowns the direct production of radionuclides at MEDICIS cannot be possible [...] MED-012.- Geneva : CERN, 2018 - 3. Fulltext: DOC;

2018-07-22
23:58
 Very high specific activity Er-169 production at MEDICIS from external ILL target / Formento Cavaier, Roberto (Centre National de la Recherche Scientifique (FR)) The new facility CERN-MEDICIS will produce isotopes using the CERN proton beam at 1.4 GeV coming from the CERN Proton Booster. However during short and long shutdowns the direct production of radionuclides at MEDICIS cannot be possible [...] MED-011.- Geneva : CERN, 2018 - 2. Fulltext: DOC;

2018-07-22
23:52
 Laser ionization yield enhancement of external targets radionuclides production at CERN-MEDICIS / Formento Cavaier, Roberto (Centre National de la Recherche Scientifique (FR)) The new facility CERN-MEDICIS will produce dedicated radioisotopes for medical applications using the CERN proton beam of 1.4 GeV coming from the CERN Proton Booster. However, during short and longer shutdowns of the CERN accelerator facilities the direct production of radionuclides at MEDICIS cannot be possible. [...] MED-010.- Geneva : CERN, 2018 - 3. Fulltext: DOC;

2018-07-22
23:41
 Study of lung tumours by using theragnostics with radioactive isotopes of Terbium In recent years, a number of nuclear-medicine techniques developed for cancer therapy are based on the use of two different radioactive isotopes of the same chemical element, one for diagnosis and the other for therapy; this is the so called theragnostics technique. The diagnostic’s radioisotope will provide the location of the tumour and will decay by gamma emission with a short half-life (hours), whereas the therapeutic radioisotope will attack the tumour by beta/alpha emission having usually a longer half-life (days). [...] MED-009.- Geneva : CERN, 2018 - 2. Fulltext: DOCX;

2018-07-22
23:26
 Development of CXCR4-targeted agents for molecular radiotherapy with 67Cu CXCR4 is overexpressed in a wide range of malignancies, and agents for the detection and endoradiotherapeutic ablation of this target are entering clinical practice based on the peptide Pentixafor and the isotope pair 68Ga/177Lu. Disadvantages have been demonstrated due to the structural variation on using the different radiometals. [...] MED-008.- Geneva : CERN, 2018 - 2. Fulltext: DOC;

2018-07-22
23:17
 Carbon release study from BN / Stegemann, Simon Thomas (KU Leuven (BE)) Hadron therapy, in par􏰀cular carbon therapy is a very precise treatment for localized cancers where the tumor is irradiated by a pure and intense carbon beam. Such a treatment reduces the dose delivery to healthy 􏰀ssue due to the very localized energy deposi􏰀on at the end of the beam trajectory (Bragg-peak). [...] MED-007.- Geneva : CERN, 2018 - 4. Fulltext: PDF;